Ultragenyx Pharmaceutical Inc.
RARE
$35.11
-$0.87-2.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 494.44M | 610.03M | 607.51M | 763.82M | 412.08M |
| Total Receivables | 102.84M | 123.60M | 95.10M | 108.28M | 100.45M |
| Inventory | 46.03M | 45.01M | 43.33M | 40.14M | 35.91M |
| Prepaid Expenses | 47.37M | 31.68M | -- | -- | -- |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 8.48M | 6.81M | 53.67M | 52.40M | 47.53M |
| Total Current Assets | 699.16M | 817.12M | 799.61M | 964.64M | 595.97M |
|
|
|||||
| Total Current Assets | 699.16M | 817.12M | 799.61M | 964.64M | 595.97M |
| Net Property, Plant & Equipment | 260.91M | 291.43M | 272.45M | 278.71M | 285.11M |
| Long-term Investments | 44.41M | 44.41M | 44.41M | 44.41M | 44.41M |
| Goodwill | 44.41M | 44.41M | 44.41M | 44.41M | 44.41M |
| Total Other Intangibles | 176.52M | 178.31M | 164.94M | 166.24M | 165.05M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 62.37M | 37.18M | 53.87M | 53.77M | 59.97M |
| Total Assets | 1.31B | 1.50B | 1.54B | 1.62B | 1.31B |
|
|
|||||
| Total Accounts Payable | 47.45M | 38.76M | 35.99M | 59.81M | 40.97M |
| Total Accrued Expenses | 173.01M | 240.97M | 185.03M | 154.42M | 149.13M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 67.86M | 60.14M | 59.16M | 58.64M | 55.47M |
| Total Finance Division Other Current Liabilities | 3.35M | 4.28M | 4.84M | -- | -- |
| Total Other Current Liabilities | 3.35M | 4.28M | 4.84M | -- | -- |
| Total Current Liabilities | 291.67M | 344.15M | 285.01M | 272.87M | 245.58M |
|
|
|||||
| Total Current Liabilities | 291.67M | 344.15M | 285.01M | 272.87M | 245.58M |
| Long-Term Debt | 794.05M | 819.82M | 829.69M | 842.16M | 848.73M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 27.79M | 30.04M | 23.66M | 25.74M | 27.98M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 47.18M | 47.14M | 46.19M | 45.26M | 44.54M |
| Total Liabilities | 1.16B | 1.24B | 1.18B | 1.19B | 1.17B |
|
|
|||||
| Common Stock & APIC | 4.25B | 4.21B | 4.17B | 4.12B | 3.70B |
| Retained Earnings | -4.11B | -3.96B | -3.82B | -3.69B | -3.56B |
| Treasury Stock & Other | -341.00K | -643.00K | 896.00K | -1.10M | -431.00K |
| Total Common Equity | 144.25M | 255.30M | 346.83M | 432.42M | 140.26M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 144.25M | 255.30M | 346.83M | 432.42M | 140.26M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | 7.00M | 7.00M | 7.00M | -- | -- |
| Total Equity | 151.25M | 262.30M | 353.83M | 432.42M | 140.26M |
|
|
|||||